Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
07:15am, Tuesday, 10'th Nov 2020
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
07:15am, Friday, 30'th Oct 2020
COPENHAGEN, Denmark & LAUSANNE, Switzerland--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and ADC Therapeutics SA (NYSE: ADCT) today announced that they have executed an amended agreement for ADC Therap
ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2020 Results - Earnings Call Transcript
08:48pm, Tuesday, 18'th Aug 2020
ADC Therapeutics SA (NYSE:ADCT) Q2 2020 Earnings Conference Call August 18, 2020, 08:30 ET Company Participants Amanda Hamilton - IR Officer Christopher Martin - CEO & Director Jay Feingold - Chie
ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights
11:15am, Tuesday, 18'th Aug 2020
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (
ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020
08:15pm, Wednesday, 12'th Aug 2020
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (
Biotech IPOs Capture Record $7.5 Billion in Second Quarter
08:42pm, Thursday, 23'rd Jul 2020
The popularity of the sector continues with 57 new companies on tap to go public Continue reading...
Karyopharm's XPOVIO Progress And Other News: The Good, Bad And Ugly Of Biopharma
01:44pm, Sunday, 19'th Jul 2020
Karyopharm collaborates with National Cancer Institute for XPOVIO. ADC Therapeutics advances LOTIS 3 Clinical Trial of Loncastuximab Tesirine.
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (A
ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly po
New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO
02:40pm, Tuesday, 30'th Jun 2020
New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfolio company, ADC Therapeutics (NYSE:ADCT). The co
ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly po
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates fo
Pliant Therapeutics Shares Have Climbed 44% Since This Week's IPO
08:01pm, Thursday, 04'th Jun 2020
Several other biotechs lined up to go public as life sciences companies gain higher profiles due to fight against the coronavirus Continue reading...
ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress
11:00am, Thursday, 21'st May 2020
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates fo
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates f
